JPM2024: Lilly CEO David Ricks Weighs In on GLP-1s and AI

With the buzz in San Francisco beginning to slow down, some in the biopharma industry are still giving their analysis and predictions for the rest of the year. Speaking on a virtual panel hosted by Boston Consulting Group, Eli Lilly CEO David Ricks noted that this week in San Francisco was “upbeat,” driven by a cheerful “innovation cycle,” and that more M&A activity was kicking off that caused a bit of excitement.